trending Market Intelligence /marketintelligence/en/news-insights/trending/wxqy-l7ipkzwds_tkfrusw2 content esgSubNav
In This List

Immunomedics seeks US FDA approval for cancer drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Immunomedics seeks US FDA approval for cancer drug

Immunomedics Inc. filed a biologics license application with the U.S. Food and Drug Administration, seeking approval for its breast cancer treatment, which is known as sacituzumab govitecan.

The treatment is an antibody-drug conjugate, or ADC, a type of biopharmaceutical drug designed to target cancer cells.

The drug is being evaluated for treating patients who have received at least two prior therapies for triple-negative breast cancer and whose disease has spread to other parts of the body.

Immunomedics said the submission was backed by the results of a phase 1/2 trial. If approved, sacituzumab govitecan would be the first and only ADC approved to treat the disease.

Morris Plains, N.J.-based Immunomedics is focused on developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other diseases.